Real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide
Apalutamide leads to faster, deeper PSA90 response vs enzalutamide in real-world patients with de novo metastatic castration-sensitive prostate cancer.
